bitFlyer Europe Launches Cross-Border Trading with Japan to Further Consolidate Global Offering
30.9.2020 07:00:00 EEST | Business Wire | Press release
Leading cryptocurrency exchange bitFlyer has announced the launch of cross-border trading on its platform. For the first time, users in Europe will be able to access one of the largest bitcoin markets in Japan, while still using a European-regulated platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200929005920/en/
bitFlyer Europe launches cross-border trading with Japan (Graphic: Business Wire)
The Japanese bitcoin market is one of the biggest in the world, with approximately 20%1 of the global BTC to FIAT (national currencies) trading volume being traded against the JPY. As Japan’s leading exchange, more than 70%2 of the JPY trading volume passes through the bitFlyer platform. This makes the launch of cross-border trading a natural next step for bitFlyer in consolidating its position as a global player.
bitFlyer is now not only the first cryptocurrency exchange that is licensed to operate in Japan, the EU, and the US combined, but is also the first to facilitate this cross-border access to its prized JPY liquidity.
Cross-border trading is of particular benefit to traders looking to handle large volumes, as the increased liquidity will allow for faster execution of trades, reducing the risk of slippage and the spread between buy and sell prices.
Andy Bryant, COO of bitFlyer Europe, said, “The launch of bitFlyer’s cross-border trading is revolutionary for the cryptocurrency industry and a huge milestone for us. Before now, it’s been virtually impossible for traders with Euros to participate in the BTC/JPY trading pair without going through multiple extra steps and/or sign up processes, bringing unwanted inconvenience and delays.
“bitFlyer is quite simply giving more of its users an unprecedented opportunity to trade in one of the largest and most liquid markets in the world. Those more experienced and successful traders will know just how important it is to seek the most liquid markets, and we’re confident with this launch we can offer a better experience for them and all our users”.
Until now, cross-border trading has posed challenges to traders as it is extremely difficult for overseas users to sign up to Japanese exchanges. bitFlyer’s cross-border trading initiative enables users to access BTC/JPY under their existing bitFlyer Europe account, without the need to open multiple accounts across multiple exchange platforms.
bitFlyer’s long-term objective is to have all spot trading pairs available across all regions, including BTC/JPY in the US, BTC/USD in Europe and Japan, and BTC/EUR in Japan and the US.
Users trading BTC/JPY via bitFlyer Europe will still be subject to the same European privacy policies and their rights will not be affected. All bitFlyer entities are regulated to the highest standards according to their jurisdictions, meaning proper controls and compliance with local AML and KYC laws.
“bitFlyer’s objective has always been to create a truly global cryptocurrency trading platform that allows users to benefit from the scale, depth and liquidity of one, single marketplace. Liquidity is a constant challenge for cryptocurrency markets and is essential to ensure the future growth and sustainability of BTC and the cryptocurrency industry as a whole. Today’s announcement is a huge step forward in that regard” says Yuzo Kano, Founder of bitFlyer group and Chairman of bitFlyer Europe.
bitFlyer Europe launched in January 2018 as a fully owned subsidiary of bitFlyer, Inc., a household name in the cryptocurrency space in Japan, and one of the longest-standing cryptocurrency exchanges. bitFlyer is the only cryptocurrency exchange to be licenced in Japan, the US and Europe combined, and has also recently been recognised as one of only 10 exchanges3 that isn’t faking trading volumes.
ENDS
About bitFlyer Europe S.A.
bitFlyer Europe S.A. is a wholly-owned subsidiary of bitFlyer, Inc., a leading bitcoin and blockchain company based in Japan. The European office is located in Luxembourg and operates an exchange platform for European traders to buy and sell virtual currencies. bitFlyer Europe S.A. site: https://bitflyer.com/en-eu/
1 https://www.coinhills.com/market/currency/
2 https://jpbitcoin.com/market/volume
3 https://www.sec.gov/comments/sr-nysearca-2019-01/srnysearca201901-5164833-183434.pdf
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200929005920/en/
Contact information
Lauren Armour
lauren.armour@tytopr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 15:03:00 EEST | Press release
Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L. Saver, MD, UCLA, and Principal Investigator of DISTALS. “What’s important is that both the device and the trial were designed specifically for distal stroke. By using a device built for these small vessels and mea
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 15:00:00 EEST | Press release
Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have faced two critical dining pain points: [Pain Point 1] The Information Gap: Most available resources are tailored for tourists, making it difficult to find the true loc
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 15:00:00 EEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
FIFA and Fanatics Expand Wide-Ranging Relationship to Include Historic Exclusive Collectibles Agreement (Trading Cards, Stickers and Trading Card Games)7.5.2026 14:00:00 EEST | Press release
In a landmark agreement expanding their already successful wide-ranging commercial relationship, FIFA and Fanatics have signed a long-term, exclusive collectibles licensing deal that features trading cards, stickers, and trading card games. The agreement, which will begin in full in 2031, covers both physical and digital collectibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507105628/en/ An example of the product innovations that will be brought to fans under this new partnership is the highly sought-after player jersey patch program, including debut patches, which will be inserted into football trading cards from 2031 onward. All products will be designed and developed through Fanatics Collectibles and produced under the Topps brand. As a part of the deal, Fanatics will bring the magic to young people in every region of the world and support youth football globally by distributing more than $150 million in collect
DEFINITIVE Trial Reaches Major Milestone: All Centres Approved and More Than 50% Recruitment Achieved7.5.2026 12:21:00 EEST | Press release
The DEFINITIVE project, a landmark European Union-funded international phase III clinical trial evaluating the use of the HER2DX diagnostic assay to guide personalised treatment in early-stage HER2-positive breast cancer (BC), announces two major operational milestones at the ESMO Breast Cancer 2026 congress. Approvals have been obtained in the 7 participating countries, 33 clinicals sites are now open for patient recruitment. The trial has reached over 50% of its recruitment target, marking a pivotal moment on the path toward to transforming HER2-positive BC treatment. About the DEFINITIVE Project The DEFINITIVE project is a 5-year, prospective, open-label, randomised, two-arm phase III international clinical trial conducted across 44 centres in 7 European member states and associated countries. The trial aims to demonstrate that personalising treatment decisions for patients with early-stage (stage II to IIIA) HER2-positive BC using the HER2DX genomic diagnostic assay can improve pat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom